Non-Valvular Atrial Fibrillation (NVAF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Non-Valvular Atrial Fibrillation (NVAF) Market Outlook

Thelansis’s “Non-Valvular Atrial Fibrillation (NVAF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Valvular Atrial Fibrillation treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Valvular Atrial Fibrillation (NVAF) Overview

Valvular atrial fibrillation (AF) is a condition where AF occurs in the presence of mitral stenosis or mechanical valve prosthesis. On the other hand, non-valvular atrial fibrillation (NVAF) refers to an irregular and often rapid heartbeat in the heart's atria. However, unlike valvular AF, it is not associated with significant heart valve issues. NVAF is the most prevalent form of atrial fibrillation. NVAF can have various nonvalvular causes, such as exposure to heart stimulants like alcohol, caffeine, or tobacco, sleep apnea, high blood pressure, lung problems, hyperthyroidism, or severe illness-related stress such as pneumonia. NVAF symptoms include discomfort in the chest, a fluttering feeling in the chest, palpitations, dizziness or near-fainting sensations, labored breathing, and fatigue. Atrial fibrillation is a common heart rhythm disorder that primarily affects the atria and significantly raises the risk of thromboembolic events, particularly ischemic stroke and systemic embolization. NVAF is a substantial risk factor for severe and potentially fatal ischemic strokes, contributing to approximately 15% of all ischemic strokes and up to 30% of strokes in individuals in their 80s. In the European Union, Dabigatran etexilate (Pradaxa) has received approval to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) who have one or more risk factors.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: